HF  Deep Track Capital

https://www.deeptrackcapital.com/




     Office Locations:

200 Greenwich Ave., 3rd Floor
Greenwich, CT 06830
Phone: 203-409-0810
 

Stages:

  • Early
  • Expansion
  • Growth
 

Industries:

  • Life Sciences & Healthcare


    		•
     

    Description:

    Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. The firm develops long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. The firm aims to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors.


     

    Funds:


      Fund Name
      Amount
      Date
    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)    		No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)    		$2M-$7M
    Expansion Stage
    (also called Late-stage)    		$7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    David Kroin Founder and Chief Investment Officer
    Gerard Smith MD/MBA Principal
    Janet Okogbaa MD Associate
    Nir Messafi CPA Chief.Operating.and.Financial.Officer, Chief.Compliance.Officer
    Rael Mazansky MD/MBA Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date
      Name
      State
      Amount
      Stage

      10/02/2024
      Triveni Bio
      MA
      $115,000,000
      Series B

      08/12/2024
      Halda Therapeutics
      CT
      $126,000,000
      Series B Extension

      08/05/2024
      MBX Biosciences
      IN
      $63,500,000
      Series C

      08/01/2024
      Jade Biosciences
      MA
      $80,000,000
      Venture

      04/03/2024
      Obsidian Therapeutics
      MA
      $160,500,000
      Series C

     

    Portfolio companies include:

     

    Recent News: